(Q51052599)

English

Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.

scientific article published in March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Helicobacter pylori

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Hong-Long Wang

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Herng-Der Chern

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Bor-Ru Lin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Chun-Jung Lin

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Teh-Hong Wang

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

0 references

publication date

1 March 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Pharmacotherapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

227-238

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Helicobacter pyloriInfection

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

H pylori antibiotic resistance: prevalence, importance, and advances in testing

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Eradication therapy for Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Eradication of Helicobacter pylori: an objective assessment of current therapies

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Bactericidal and morphological effects of amoxicillin on Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.227

21 January 2018

Identifiers

10.1592/PHCO.31.3.227

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21361732%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51052599&oldid=2112203910"